Fig. 6
From: CanSeer: a translational methodology for developing personalized cancer models and therapeutics
Therapeutic outcome of lung squamous cell carcinoma case study. Employing CanSeer helped identify 4 mono-targeted drugs and 2 drug combinations, which has already been approved by FDA for non-small cell lung cancer (please note that lung squamous cell carcinoma is a sub-type of non-small cell lung cancer). 26 such drugs or combinations were identified that are currently under investigation or reported in various scientific studies for lung cancer especially non-small cell lung cancer. 20 drug combinations predicted for lung squamous cell carcinoma, are previously known, or approved for various other cancer types, suggesting the potential for repositioning. Moreover, CanSeer revealed 97 novel drug combination candidates for lung squamous cell carcinoma (literature validation shown in S15). These four broad categories of drugs or drug combinations are demonstrated through a circos plot.
